Chronic Obstructive Pulmonary Disease Exacerbation, COPD
Conditions
Brief summary
The aim of this trial is to assess the potential key drug-drug interactions with EP395 in the clinical setting.
Detailed description
This is an open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the effect of EP395 on systemic exposure of midazolam and digoxin (Part B). The overall aim of this trial is to assess the potential key drug-drug interactions (DDIs) with EP395 in the clinical setting. The trial will be in two parts: Part A will investigate EP395 as a 'victim' of DDIs. The impact of CYP3A4 and P-glycoprotein (Pgp) inhibition on the pharmacokinetics (PK) of EP395 will be assessed. Verapamil has been selected as a moderate inhibitor of CYP3A4 and an inhibitor of Pgp. Part B will investigate EP395 as a 'perpetrator' of DDIs. The impact of EP395 on the PK of a CYP3A4 substrate and a Pgp substrate will be assessed. Midazolam has been selected as the CYP3A4 substrate and digoxin as the Pgp substrate. The trial population is healthy adults.
Interventions
DRUGEP395 (Part A and B)
EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg. Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg.
Verapamil (CYP3A4/Pgp inhibitor), tablet 40 mg. Part A: Dose: 3 tablets twice daily Days 10 to 18, total daily dose: 240 mg.
DRUGMidazolam (Part B)
Midazolam (CYP3A4 substrate) oral solution 1 mg/mL. Part B: Dose: 4 mL as a single dose on Day 1 and Day 24, total daily dose: 4 mg.
DRUGDigoxin (Part B)
Digoxin (Pgp substrate) tablet 0.25 mg. Part B: Dose: 1 tablet as a single dose on Day 1 and Day 24, total daily dose: 0.25 mg.
Sponsors
EpiEndo Pharmaceuticals
CTC Clinical Trial Consultants AB
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a single centre, open label trial to assess the impact of CYP3A4 and Pgp inhibition on the PK of EP395 (Part A); and, to assess the impact of EP395 on the PK of a CYP3A4 substrate and a Pgp substrate (Part B). Parts A and B of the trial may be conducted concurrently.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Willing and able to understand the information on the nature, the scope, and the relevance of the trial, and to provide voluntary, written informed consent to participate in the trial before any trial-related procedures. 2. Healthy male or female participant aged 18 to 55 years, inclusive. 3. Body mass index ≥ 19.0 and ≤ 33.0 kg/m2 at the time of the screening visit. 4. Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG and laboratory values at the time of the screening visit, as judged by the Investigator. 5. Non-smoker, or former smoker with \<10 pack years who stopped smoking (including e-cigarettes) at least 6 months before the screening visit. 6. Women of childbearing potential (WOCBP) must: 1. have a negative pregnancy test (blood) at the screening visit and (urine) Day 1. 2. agree to use, and be able to comply with, highly effective measures of contraceptive control (failure rate less than 1% per year when used consistently and correctly) without interruption, during trial participation and until 90 days after the last IMP intake. 3. agree to abstain from breast feeding during the trial participation and for 90 days after the last IP intake. Women defined as of non-childbearing potential are postmenopausal (no menses for at least 1 year without alternative medical cause \[follicle stimulating hormone, FSH, measurement in serum may be done as additional confirmation at Investigator's discretion\]) or surgically sterile women (tubal ligation, hysterectomy, or bilateral oophorectomy). Men must agree to use a condom during sexual intercourse with WOCBP during treatment and for 90 days after the last IP intake and should not donate sperm during this time.
Exclusion criteria
Participants must not enter the trial if any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: PK parameters of EP395 - AUC0-24 | Days 1 to 6 and Day 14 to 19 | Area under the plasma concentration vs. time curve from timepoint 0 to 24 hours of EP395. |
| Part A: PK parameters of EP395 - AUC0-inf | Days 1 to 6 and Day 14 to 19 | Area under the plasma concentration vs. time curve from timepoint 0 to infinity of EP395. |
| Part A: PK parameters of EP395 - AUC%extrap | Days 1 to 6 and Day 14 to 19 | Percent of AUCinf derived from extrapolation of the plasma concentration vs. time curve of EP395. |
| Part A: PK parameters of EP395 - CL/F | Days 1 to 6 and Day 14 to 19 | Apparent total body clearance following extravascular administration of EP395. |
| Part A: PK parameters of EP395 - Cmax | Days 1 to 6 and Day 14 to 19 | Maximum observed plasma concentration of EP395. |
| Part A: PK parameters of EP395 - Tmax | Days 1 to 6 and Day 14 to 19 | Time to occurrence of Cmax of EP395. |
| Part A: PK parameters of EP395 - T1/2 | Days 1 to 6 and Day 14 to 19 | Terminal elimination half-life of EP395. |
| Part A: PK parameters of EP395 - Vz/F | Days 1 to 6 and Day 14 to 19 | Volume of distribution following extravascular administration of EP395. |
| Part B: PK parameters of midazolam and digoxin - AUC0-24 | Days 1 to 3/6 and Day 24 to 29 | Area under the plasma concentration vs. time curve from timepoint 0 to 24 hours of midazolam and digoxin. |
| Part B: PK parameters of midazolam and digoxin - AUC0-inf | Days 1 to 3/6 and Day 24 to 29 | Area under the plasma concentration vs. time curve from timepoint 0 to infinity of midazolam and digoxin. |
| Part B: PK parameters of midazolam and digoxin - AUC%extrap | Days 1 to 3/6 and Day 24 to 29 | Percent of AUCinf derived from extrapolation of the plasma concentration vs. time curve of midazolam and digoxin. |
| Part B: PK parameters of midazolam and digoxin - Cmax | Days 1 to 3/6 and Day 24 to 29 | Maximum observed plasma concentration of midazolam and digoxin. |
| Part B: PK parameters of midazolam and digoxin - Tmax | Days 1 to 3/6 and Day 24 to 29 | Time to occurrence of Cmax of midazolam and digoxin. |
| Part B: PK parameters of midazolam and digoxin - T1/2 | Days 1 to 3/6 and Day 24 to 29 | Terminal elimination half-life of midazolam and digoxin. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Assessment of adverse event occurrence | From screening to Day 30. | — |
| Part A: Absolute change from baseline in vital signs (Systolic and diastolic blood pressure) | Screening (Day -28 to Day -1), Day 1, Day 10-19 | Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant. |
| Part A: Absolute change from baseline in vital signs (Pulse) | Screening (Day -28 to Day -1), Day 1, Day 10-19 | Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant. |
| Part A: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (heart rate) | Screening (Day -28 to Day -1), Day 1, Day 10-19 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting heart rate (HR) will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part A: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (PQ/PR interval) | Screening (Day -28 to Day -1), Day 1, Day 10-19 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting PQ/PR interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part A: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (QRS interval) | Screening (Day -28 to Day -1), Day 1, Day 10-19 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting QRS interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part A: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (QT interval) | Screening (Day -28 to Day -1), Day 1, Day 10-19 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting QT interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part A: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (QTcF interval) | Screening (Day -28 to Day -1), Day 1, Day 10-19 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting QTcF interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part A: Absolute change from baseline in safety laboratory analytes (haematology). | Screening (Day -28 to Day -1), Day -1, Day 10, Day 14, Day 19 | Erythrocyte count, Leukocyte count with differential count, Haematocrit (EVF), Haemoglobin (Hb), Mean corpuscular haemoglobin (MCH), Mean corpuscular volume (MCV), Platelet count. Absolute changes from baseline will be summarized for all assessed time points. |
| Part A: Absolute change from baseline in safety laboratory analytes (clinical chemistry). | Screening (Day -28 to Day -1), Day -1, Day 10, Day 14, Day 19 | Alanine aminotransferase (ALT), Albumin, Alkaline phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Creatinine (estimated Glomerular Filtration Rate \[eGFR\] included), Gamma glutamyl transferase, Glucose (non-fasting, at screening only), Lactate dehydrogenase, Phosphate, Potassium, Protein (total), Sodium, Urea Absolute changes from baseline will be summarized for all assessed time points. |
| Part A: Absolute change from baseline in safety laboratory analytes (coagulation). | Screening (Day -28 to Day -1), Day -1, Day 10, Day 14, Day 19 | Activated Partial Thromboplastin Time (APTT), Prothrombin Complex International Normalised Ratio (PK\[INR\]) Absolute changes from baseline will be summarized for all assessed time points. |
| Part B: Assessment of adverse event occurrence | From screening to Day 30. | — |
| Part B: Absolute change from baseline in vital signs (Systolic and diastolic blood pressure) | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in vital signs (Pulse) | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Any vital signs outside of normal ranges will be judged as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (heart rate). | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting heart rate (HR) will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (PQ/PRinterval). | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting PQ/PR interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (QRS interval). | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting QRS interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (QT interval). | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting QT interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters (QTcF interval). | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting QTcF interval will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in 12-lead Electrocardiogram (ECG) parameters | Screening (Day -28 to Day -1), Day 1, Day 9, Day 16, Day 24, Day 28 | Number of patients with any clinically significant change in 12-lead Electrocardiogram (ECG) parameters. The resting heart rate (HR) and PQ/PR, QRS, QT and QTcF intervals will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant. |
| Part B: Absolute change from baseline in safety laboratory analytes (haematology). | Screening (Day -28 to Day -1), Day -1, Day 9, Day 16, Day 23, D28 | Erythrocyte count, Leukocyte count with differential count, Haematocrit (EVF), Haemoglobin (Hb), Mean corpuscular haemoglobin (MCH), Mean corpuscular volume (MCV), Platelet count. Absolute changes from baseline will be summarized for all assessed time points. |
| Part B: Absolute change from baseline in safety laboratory analytes (clinical chemistry). | Screening (Day -28 to Day -1), Day -1, Day 9, Day 16, Day 23, D28 | Alanine aminotransferase (ALT), Albumin, Alkaline phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Creatinine (estimated Glomerular Filtration Rate \[eGFR\] included), Gamma glutamyl transferase, Glucose (non-fasting, at screening only), Lactate dehydrogenase, Phosphate, Potassium, Protein (total), Sodium, Urea Absolute changes from baseline will be summarized for all assessed time points. |
| Part B: Absolute change from baseline in safety laboratory analytes (coagulation). | Screening (Day -28 to Day -1), Day -1, Day 9, Day 16, Day 23, D28 | Activated Partial Thromboplastin Time (APTT), Prothrombin Complex International Normalised Ratio (PK\[INR\]) Absolute changes from baseline will be summarized for all assessed time points. |
| Part B: PK parameters of EP395 and its major metabolites (Cmax) | Days 1 to 3/6 and Day 24 to 29 | The ratios of EP395 metabolite to parent systemic exposures in terms of Cmax and AUC0-24 will be calculated and expressed as percentages. |
| Part B: PK parameters of EP395 and its major metabolites (AUC0-24) | Days 1 to 3/6 and Day 24 to 29 | The ratios of EP395 metabolite to parent systemic exposures in terms of Cmax and AUC0-24 will be calculated and expressed as percentages. |
Countries
Sweden
Contacts
PRINCIPAL_INVESTIGATORBjörn Schultze, MD
CTC Clinical Trial Consultants AB
Outcome results
None listed